ramucirumab,paclitaxel
eli lilly
[]
. s dr. howard hochster ( ) &amp; colleagues present randomized, phase ii selection study of ramucirumab and paclitaxel versus folfiri in refractory small bowel #adenocarcinoma: swog s1922 #gi23 
Rutgers Cancer Institute of New Jersey is the state’s only NCI-designated Comprehensive Cancer Center and a leader in patient care and cancer research.